Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system.

被引：0
|
作者：
Tanaka, Y
Tokunaga, M
Kawabata, D
Imura, Y
Fujii, T
Nawata, M
Tsujimura, S
Nakayamada, S
Mimoro, T
Saito, K
机构：
[1] Univ Occupat & Environm Hlth, Kitakyushu, Fukuoka 807, Japan
[2] Kyoto Univ, Grad Sch Med, Kyoto, Japan
来源：
ARTHRITIS AND RHEUMATISM | 2005年 / 52卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S191 / S191
页数：1
相关论文
共 50 条
  • [21] Anti-CD20 therapy in systemic lupus erythematosus: A step closer to the clinic
    Silverman, GJ
    ARTHRITIS AND RHEUMATISM, 2005, 52 (02): : 371 - 377
  • [22] Anti-CD20 therapy in patients with refractory systemic lupus erythematosus: a longitudinal analysis of 52 Hispanic patients
    Garcia-Carrasco, M.
    Mendoza-Pinto, C.
    Sandoval-Cruz, M.
    Soto-Vega, E.
    Beltran-Castillo, A.
    Jimenez-Hernandez, M.
    Graillet, D.
    Gonzalez, L.
    Rojas-Rodriguez, J.
    Pineda-Almazana, A.
    Zamudio-Huerta, L.
    Lopez-Colombo, A.
    LUPUS, 2010, 19 (02) : 213 - 219
  • [23] Imaging and Therapy with Rituximab Anti-CD20 Immunotherapy in an Animal Model of Central Nervous System Lymphoma
    Muldoon, Leslie L.
    Lewin, Seth J.
    Dosa, Edit
    Kraemer, Dale F.
    Pagel, Michael A.
    Doolittle, Nancy D.
    Neuwelt, Edward A.
    CLINICAL CANCER RESEARCH, 2011, 17 (08) : 2207 - 2215
  • [24] Humanized anti-CD20 monoclonal antibody in the treatment of severe resistant systemic lupus erythematosus in a patient with antibodies against rituximab
    Tahir, H
    Rohrer, J
    Bhatia, A
    Wegener, WA
    Isenberg, DA
    RHEUMATOLOGY, 2005, 44 (04) : 561 - 562
  • [25] Anti-CD20 monoclonal antibody (Rituximab) for life-threatening autoimmune haemolytic anaemia in a patient with systemic lupus erythematosus
    Perrotta, S
    Locatelli, F
    La Manna, A
    Cennamo, L
    De Stefano, P
    Nobili, B
    BRITISH JOURNAL OF HAEMATOLOGY, 2002, 116 (02) : 465 - 467
  • [26] An open-label safety and efficacy study of an anti-CD20 antibody (rituximab, Rituxan) for anti-B-cell therapy in the treatment of systemic lupus erythematosus
    RA Eisenberg
    S Khan
    J Stansberry
    D Tsai
    S Kolasinski
    E Rieder
    B Kotzin
    RJ Looney
    C Strieber
    D Albert
    Arthritis Res Ther, 6 (Suppl 3):
  • [27] Imaging and therapy with rituximab anti-CD20 immunotherapy in an animal model of central nervous system lym phoma
    Muldoon, Leslie L.
    Lewin, Seth J.
    Dosa, Edit
    Pagel, Michael A.
    Doolittle, Nancy D.
    Neuwelt, Edward A.
    CANCER RESEARCH, 2011, 71
  • [28] Long-term efficacy of anti-CD20 antibodies in refractory lupus nephritis
    Alejandro Arce-Salinas, C.
    Rodriguez-Garcia, Felipe
    Ivan Gomez-Vargas, J.
    RHEUMATOLOGY INTERNATIONAL, 2012, 32 (05) : 1245 - 1249
  • [29] Long-term efficacy of anti-CD20 antibodies in refractory lupus nephritis
    C Alejandro Arce-Salinas
    Felipe Rodríguez-García
    J Iván Gómez-Vargas
    Rheumatology International, 2012, 32 : 1245 - 1249
  • [30] A Phase I trial of B-cell depletion with anti-CD20 monoclonal antibody (rituximab) in the treatment of systemic lupus erythematosus
    R Eisenberg
    D Albert
    J Stansberry
    D Tsai
    S Kolasinski
    S Khan
    Arthritis Res Ther, 5
12345